Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...